CN114045233B - Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof - Google Patents

Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof Download PDF

Info

Publication number
CN114045233B
CN114045233B CN202111293299.0A CN202111293299A CN114045233B CN 114045233 B CN114045233 B CN 114045233B CN 202111293299 A CN202111293299 A CN 202111293299A CN 114045233 B CN114045233 B CN 114045233B
Authority
CN
China
Prior art keywords
parts
bowel syndrome
irritable bowel
fermentation
bla80
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111293299.0A
Other languages
Chinese (zh)
Other versions
CN114045233A (en
Inventor
方曙光
董瑶
汪欣
朱建国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yiweierkang Biotechnology Co ltd
Original Assignee
Shanghai Yiweierkang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yiweierkang Biotechnology Co ltd filed Critical Shanghai Yiweierkang Biotechnology Co ltd
Priority to CN202111293299.0A priority Critical patent/CN114045233B/en
Publication of CN114045233A publication Critical patent/CN114045233A/en
Application granted granted Critical
Publication of CN114045233B publication Critical patent/CN114045233B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
    • A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/123—Bulgaricus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/21—Streptococcus, lactococcus
    • A23V2400/249—Thermophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis

Abstract

The invention relates to a direct-vat-set fermentation inoculant for relieving constipation type irritable bowel syndrome, and a preparation method and application thereof, wherein the direct-vat-set fermentation inoculant for relieving constipation type irritable bowel syndrome comprises streptococcus thermophilus ST81 fermented product, lactobacillus bulgaricus LB42 fermented product, bifidobacterium lactis BLa80 fermented product and a protective agent. The bifidobacterium lactis Bla80 plays a key role in regulating intestinal health and relieving constipation type irritable bowel syndrome, and is combined with streptococcus thermophilus ST81 and lactobacillus bulgaricus LB42, so that on one hand, three bacterial groups are mutually promoted, the fermentation process is facilitated, the growth of beneficial bacterial groups is promoted, on the other hand, the three bacterial groups are mutually matched, the bifidobacterium lactis Bla80 has a remarkable synergistic effect on regulating intestinal bacterial groups and relieving constipation type irritable bowel syndrome, and the prepared fermented food can improve symptoms such as constipation and abdominal pain, so that defecation is smoother, and constipation type irritable bowel syndrome is effectively relieved.

Description

Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof
Technical Field
The invention belongs to the technical field of food processing, relates to a direct-vat-set fermentation inoculant, a preparation method and application thereof, and in particular relates to a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, and a preparation method and application thereof.
Background
Irritable bowel syndrome (irritable bowel syndrome, IBS) is a group of continuous or intermittent episodes that change from abdominal pain, bloating, bowel habits and/or stool traits to clinical manifestations, lacking gastrointestinal structural and biochemical abnormalities in intestinal dysfunction. Constipation-predominant irritable bowel syndrome (IBS-C) is one of the more common types of irritable bowel syndrome. Patients may develop a series of digestive tract symptoms such as abdominal pain, abdominal distention, abdominal discomfort, etc., and may also be accompanied by psychological problems such as anxiety, depression, etc. At present, the constipation type irritable bowel syndrome is mainly treated by medicaments.
For example, CN112843143a discloses a traditional Chinese medicine composition for treating constipation type irritable bowel syndrome, and its medicament and application, the raw materials composition is as follows: magnolia bark, magnolia flower, immature bitter orange, sea buckthorn, kelp, fructus cannabis, bighead atractylodes rhizome, chinese angelica, fructus aurantii, cistanche and mulberry. The composition is prepared into a common pharmaceutical formulation by adding pharmaceutically conventional auxiliary materials according to a pharmaceutically conventional process. The traditional Chinese medicine composition disclosed by the invention has definite curative effects on constipation type irritable bowel syndrome in animal experiments and clinical symptoms.
CN109731092a discloses a traditional Chinese medicine composition for treating constipation type irritable bowel syndrome and a preparation method thereof. The composition comprises the following raw materials: bupleurum, immature bitter orange, white paeony root, hemp seed, betel nut, coptis root, garden euphorbia herb, fiveleaf akebia fruit, malva seed, dried ginger, tuckahoe, grosvener siraitia and liquorice. The medicines are matched according to a specific weight proportion, so that the medicine can treat both liver and spleen, tonify and concurrent, and both principal and secondary aspects of the disease are achieved, the effects of resolving turbidity and detoxifying, and clearing viscera and discharging turbidity are achieved, the symptoms of constipation, abdominal pain and the like of IBS-C can be effectively improved, the curative effect is clear, the cure rate is high, the recurrence rate is low, the price is low, and the treatment cost of IBS-C can be reduced.
The drug therapy disclosed in the prior art has good treatment effect on constipation type irritable bowel syndrome, however, the drug therapy often causes a certain degree of dependence, once a patient stops using the drug, constipation recurs, and the drug therapy may generate side effects such as headache, abdominal pain, diarrhea, cardiovascular diseases and the like.
Therefore, how to develop a new method of non-drug treatment for constipation-predominant irritable bowel syndrome is a problem to be solved by those skilled in the art.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a direct-vat-set fermentation inoculant, a preparation method and application thereof, and particularly provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, and a preparation method and application thereof.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the invention provides a direct-vat-set starter for relieving constipation-predominant irritable bowel syndrome, which comprises a streptococcus thermophilus ST81 ferment, a lactobacillus bulgaricus LB42 ferment, a bifidobacterium lactis BLa80 ferment and a protective agent.
The invention creatively combines the streptococcus thermophilus ST81 ferment, the lactobacillus bulgaricus LB42 ferment and the bifidobacterium lactis Bla80 ferment to form the direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome. The bifidobacterium lactis belongs to probiotics, can play a role in regulating intestinal flora by directly supplementing probiotics in vivo, and can inhibit the growth of harmful flora, so that the intestinal tract maintains a normal microenvironment, and the intestinal tract health is facilitated. It has certain regulating effect on functional enteropathy including irritable bowel syndrome, intestinal dysfunction, chronic diarrhea, abdominal distention and even chronic constipation. The streptococcus thermophilus is lactic acid bacteria, has the effects of improving the microbial environment of the gastrointestinal tract, reducing the pH value of the intestinal tract, promoting intestinal peristalsis, preventing the colonization of pathogenic bacteria, secreting bacteriocin to inhibit the growth of the pathogenic bacteria, inhibiting the activity of cholesterol synthase and reducing the cholesterol content in serum. The fermentation product can regulate and control blood pressure, and the products such as polysaccharide, bacteriocin, lactic acid and the like produced by fermentation have the effect of anti-tumor activity, and can resist tumor occurrence by activating an organism immune system and inhibiting cell mutation, and the superoxide dismutase produced by fermentation can remove excessive superoxide anion free radicals produced in the in-vivo metabolic process and delay aging. The lactobacillus bulgaricus also belongs to lactobacillus, has the effects of helping lactose fermentation and promoting digestion and absorption, can inhibit the growth and development of harmful flora in intestinal tracts, has the effect of regulating the intestinal flora, can activate the immune function in the intestinal tracts, can inhibit cancer cell proliferation, and has certain anti-inflammatory and antibacterial effects. In the direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, the bifidobacterium lactis BLa80 plays a key role in regulating intestinal health and relieving constipation-type irritable bowel syndrome, and is combined with the streptococcus thermophilus ST81 and the lactobacillus bulgaricus LB42, so that on one hand, three bacterial groups mutually promote, the fermentation process is facilitated, the growth of beneficial bacterial groups is promoted, on the other hand, the three bacterial groups mutually cooperate, the direct-vat-set fermentation inoculant has a remarkable synergistic effect on regulating intestinal bacterial groups and relieving constipation-type irritable bowel syndrome, and the prepared fermented food can improve symptoms such as constipation and abdominal pain, so that defecation is smoother, and constipation-type irritable bowel syndrome is effectively relieved.
Preferably, the direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome comprises, by weight, 25-45 parts of streptococcus thermophilus ST81 ferment, 1.5-2.5 parts of lactobacillus bulgaricus LB42 ferment, 2.5-65 parts of bifidobacterium lactis BLa80 ferment and 18-36 parts of protective agent.
Specific values of the 25 to 45 parts may be 25 parts, 27 parts, 29 parts, 31 parts, 33 parts, 35 parts, 37 parts, 39 parts, 41 parts, 43 parts, 45 parts, and the like.
Specific values of the above 1.5 to 2.5 parts may be 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2 parts, 2.1 parts, 2.2 parts, 2.3 parts, 2.4 parts, 2.5 parts, etc.
Specific values of the above 2.5 to 65 parts may be 2.5 parts, 3 parts, 3.5 parts, 4 parts, 8 parts, 12 parts, 16 parts, 20 parts, 24 parts, 28 parts, 32 parts, 36 parts, 40 parts, 44 parts, 48 parts, 52 parts, 56 parts, 60 parts, 62 parts, 65 parts, and the like.
Specific values of the 18-36 parts may be 18 parts, 19 parts, 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts, 31 parts, 32 parts, 33 parts, 34 parts, 35 parts, 36 parts, and the like.
Preferably, the viable count of bifidobacterium lactis BLa80 in the direct-vat-set fermentation starter for relieving constipation-predominant irritable bowel syndrome is 1×10 11 cfu/g or more, e.g. 1X 10 11 cfu/g、2×10 11 cfu/g、3×10 11 cfu/g、 4×10 11 cfu/g、6×10 11 cfu/g、8×10 11 cfu/g、9×10 11 cfu/g、1×10 12 cfu/g, etc.
Preferably, the protecting agent includes any one or a combination of at least two of trehalose, maltodextrin, beta-cyclodextrin, sucrose, glycerol, mannitol or tween-80, for example, a combination of trehalose and maltodextrin, a combination of beta-cyclodextrin and sucrose, a combination of sucrose and glycerol, etc., and any other combination is optional, and will not be described herein, preferably trehalose, maltodextrin, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80.
The combination of trehalose, malt paste, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80 as a protective agent has the effect of improving the stability of the prepared fermented food compared with other options.
Preferably, the protective agent comprises 12-18 parts by weight of trehalose, 2.5-8.5 parts by weight of maltodextrin, 1.0-1.5 parts by weight of beta-cyclodextrin, 2-5 parts by weight of sucrose, 1.2-2.4 parts by weight of glycerol, 0.01-0.3 part by weight of mannitol and 0.02-0.25 part by weight of tween-80.
Specific values of the above 12 to 18 parts may be 12 parts, 12.5 parts, 13 parts, 13.5 parts, 14 parts, 14.5 parts, 15 parts, 15.5 parts, 16 parts, 16.5 parts, 17 parts, 17.5 parts, 18 parts, etc.
Specific values among the above 2.5 to 8.5 parts may be 2.5 parts, 2.7 parts, 3 parts, 3.2 parts, 3.5 parts, 3.7 parts, 4 parts, 4.2 parts, 4.5 parts, 4.7 parts, 5 parts, 5.2 parts, 5.5 parts, 5.7 parts, 6 parts, 6.2 parts, 6.5 parts, 6.7 parts, 7 parts, 7.2 parts, 7.5 parts, 7.7 parts, 8 parts, 8.2 parts, 8.5 parts, etc.
Specific values of the above 1.0 to 1.5 parts may be 1 part, 1.15 parts, 1.2 parts, 1.25 parts, 1.3 parts, 1.35 parts, 1.4 parts, 1.45 parts, 1.5 parts, etc.
Specific values of the above 2 to 5 parts may be 2 parts, 2.2 parts, 2.5 parts, 2.7 parts, 3 parts, 3.2 parts, 3.5 parts, 3.7 parts, 4 parts, 4.2 parts, 4.5 parts, 4.7 parts, 5 parts, etc.
Specific values of the above 1.2 to 2.4 parts may be 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2 parts, 2.1 parts, 2.2 parts, 2.3 parts, 2.4 parts, etc.
Specific values of the above 0.01 to 0.3 parts may be 0.01 part, 0.03 part, 0.05 part, 0.07 part, 0.1 part, 0.12 part, 0.15 part, 0.17 part, 0.2 part, 0.22 part, 0.25 part, 0.27 part, 0.3 part, and the like.
Specific values among the above 0.02 to 0.25 parts may be 0.02 part, 0.04 part, 0.06 part, 0.08 part, 0.1 part, 0.12 part, 0.15 part, 0.17 part, 0.2 part, 0.22 part, 0.25 part, and the like.
In a second aspect, the present invention provides a method for preparing a direct-vat set fermentation starter for alleviating constipation-predominant irritable bowel syndrome according to the first aspect, the method comprising the steps of:
(1) Culturing and activating Streptococcus thermophilus ST81, and fermenting to obtain Streptococcus thermophilus ST81 fermented product; culturing and activating Lactobacillus bulgaricus LB42, and fermenting to obtain Lactobacillus bulgaricus LB42 fermented product; culturing and activating the bifidobacterium lactis BLa80, and fermenting to obtain a bifidobacterium lactis BLa80 fermentation product;
(2) Mixing the streptococcus thermophilus ST81 fermentation product, the lactobacillus bulgaricus LB42 fermentation product and the bifidobacterium lactis Bla80 fermentation product obtained in the step (1) with a protective agent to obtain the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome.
Preferably, the temperature of the culture of Streptococcus thermophilus ST81, the temperature of the culture of Lactobacillus bulgaricus LB42 and the temperature of the culture of Bifidobacterium lactis Bla80 in step (1) are each independently 35-40 ℃, e.g., 35 ℃, 35.5 ℃, 36 ℃, 36.5 ℃, 37 ℃, 37.5 ℃, 38 ℃, 38.5 ℃, 39 ℃, 39.5 ℃, 40 ℃, etc.
Preferably, the time of the culture of Streptococcus thermophilus ST81, the time of the culture of Lactobacillus bulgaricus LB42 and the time of the culture of Bifidobacterium lactis Bla80 in step (1) are each independently 16-24 hours, such as 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, etc.
Preferably, the temperature of fermentation of Streptococcus thermophilus ST81, the temperature of fermentation of Lactobacillus bulgaricus LB42 and the temperature of fermentation of Bifidobacterium lactis BLa80 in step (1) are each independently 35-40 ℃, e.g. 35 ℃, 35.5 ℃, 36 ℃, 36.5 ℃, 37 ℃, 37.5 ℃, 38 ℃, 38.5 ℃, 39 ℃, 39.5 ℃, 40 ℃, etc.
Preferably, the fermentation time of Streptococcus thermophilus ST81, the fermentation time of Lactobacillus bulgaricus LB42 and the fermentation time of Bifidobacterium lactis Bla80 in step (1) are each independently 9-12h, such as 9h, 9.2h, 9.5h, 9.7h, 10h, 10.2h, 10.5h, 10.7h, 11h, 11.2h, 11.5h, 11.7h, 12h, etc.
Preferably, the pH of the system in step (1) in the fermentation of Streptococcus thermophilus ST81, the pH of the system in the fermentation of Lactobacillus bulgaricus LB42 and the pH of the system in the fermentation of Bifidobacterium lactis BLa80 are each independently 5.5-6.0, e.g. 5.5, 5.55, 5.6, 5.65, 5.7, 5.75, 5.8, 5.85, 5.9, 5.95, 6, etc.
Preferably, step (1) further optionally comprises centrifugation to collect fermentation products after fermentation of Streptococcus thermophilus ST81, after fermentation of Lactobacillus bulgaricus LB42 and after fermentation of Bifidobacterium lactis Bla 80.
Preferably, the rotational speed of the centrifugation is each independently 6000-10000r/min, e.g. 6000r/min, 6500r/min, 7000r/min, 7500r/min, 8000r/min, 8500r/min, 9000r/min, 9500 r/min, 10000r/min etc.
The centrifugation time is 10-15min, such as 10min, 10.5min, 11min, 11.5min, 12min, 12.5min, 13min, 13.5min, 14min, 14.5min, 15min, etc., independently.
Preferably, the mixing in step (2) further comprises drying.
Preferably, the drying mode is freeze drying.
In a third aspect, the present invention provides a use of a direct vat set starter for alleviating constipation-predominant irritable bowel syndrome according to the first aspect in the preparation of a fermented food, wherein the inoculum size of the direct vat set starter for alleviating constipation-predominant irritable bowel syndrome is 20-50g/T, e.g. 20g/T, 22g/T, 25g/T, 27g/T, 30g/T, 32g/T, 35g/T, 37g/T, 40g/T, 42g/T, 45g/T, 47g/T, 50g/T, etc. The T represents ton.
Preferably, the fermented food includes any one of fermented soybean milk, fermented soybean powder, fermented milk or fermented milk powder.
In a fourth aspect, the invention provides fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, which comprises soybean flour, gum base, water and a direct-vat-set starter for relieving constipation-predominant irritable bowel syndrome according to the first aspect.
Preferably, the preparation raw materials of the fermented soybean milk for relieving constipation-type irritable bowel syndrome comprise, by mass, 0.002-0.005% of a direct-vat starter for relieving constipation-type irritable bowel syndrome, 10-28% of soybean flour, 3-20% of a gum base and the balance of water.
Specific values of the above 0.002 to 0.005% may be 0.002%, 0.0022%, 0.0025%, 0.0027%, 0.003%, 0.0032%, 0.0035%, 0.0037%, 0.004%, 0.0042%, 0.0045%, 0.0047%, 0.005% and the like.
Specific values of the above 10 to 28% may be 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28% and the like.
Specific values in the above 3 to 20% may be 3%, 4%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20% and the like.
Preferably, the gum base includes any one or a combination of at least two of coconut pulp, white granulated sugar, agar, pectin, citrus fiber or sea salt, for example, a combination of coconut pulp and white granulated sugar, a combination of agar and pectin, a combination of pectin and citrus fiber, etc., and any other combination mode may be selected, which will not be described in detail herein, preferably a combination of coconut pulp, white granulated sugar, agar, pectin, citrus fiber and sea salt.
Preferably, the gum base comprises, by weight, 3-10 parts of coconut milk, 1-5 parts of white granulated sugar, 0.1-1 part of agar, 0.1-0.8 part of pectin, 0.2-0.8 part of citrus fiber and 0.01-0.1 part of sea salt.
Specific values of the 3-10 parts may be 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, etc.
Specific values of the above 1 to 5 parts may be 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, etc.
Specific values of the above 0.1 to 1 part may be 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part, etc.
Specific values among the above 0.1 to 0.8 parts may be 0.1 part, 0.15 part, 0.2 part, 0.25 part, 0.3 part, 0.35 part, 0.4 part, 0.45 part, 0.5 part, 0.55 part, 0.6 part, 0.65 part, 0.7 part, 0.75 part, 0.8 part, and the like.
Specific values of the above 0.2 to 0.8 parts may be 0.2 parts, 0.25 parts, 0.3 parts, 0.35 parts, 0.4 parts, 0.45 parts, 0.5 parts, 0.55 parts, 0.6 parts, 0.65 parts, 0.7 parts, 0.75 parts, 0.8 parts, etc.
Specific values among the above 0.01 to 0.1 parts may be 0.01 part, 0.015 part, 0.02 part, 0.025 part, 0.03 part, 0.035 part, 0.04 part, 0.045 part, 0.05 part, 0.055 part, 0.06 part, 0.065 part, 0.07 part, 0.075 part, 0.08 part, 0.085 part, 0.09 part, 0.095 part, 0.1 part, and the like.
In a fifth aspect, the present invention provides a method for preparing fermented soybean milk for alleviating constipation-predominant irritable bowel syndrome according to the fourth aspect, the method comprising mixing bean flour, gum base and water, homogenizing, sterilizing, inoculating a direct-vat-set fermentation starter for alleviating constipation-predominant irritable bowel syndrome, fermenting, and demulsifying to obtain the fermented soybean milk for alleviating constipation-predominant irritable bowel syndrome.
Preferably, the temperature of the mixing is 60-90 ℃, e.g., 60 ℃, 62 ℃, 65 ℃, 67 ℃, 70 ℃, 72 ℃, 75 ℃, 77 ℃, 80 ℃, 82 ℃, 85 ℃, 87 ℃, 90 ℃, etc.
Preferably, the inoculation temperature is 38-50deg.C, such as 38deg.C, 39deg.C, 40deg.C, 41 deg.C, 42 deg.C, 43 deg.C, 44 deg.C, 45 deg.C, 46 deg.C, 47 deg.C, 48 deg.C, 49 deg.C, 50 deg.C, etc.
Preferably, the fermentation temperature is 38-50deg.C, such as 38deg.C, 39deg.C, 40deg.C, 41 deg.C, 42 deg.C, 43 deg.C, 44 deg.C, 45 deg.C, 46 deg.C, 47 deg.C, 48 deg.C, 49 deg.C, 50 deg.C, etc.
The numerical ranges recited herein include not only the recited point values, but also any point values between the recited numerical ranges that are not recited, and are limited to, and for the sake of brevity, the invention is not intended to be exhaustive of the specific point values that the recited range includes.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively combines the streptococcus thermophilus ST81 ferment, the lactobacillus bulgaricus LB42 ferment and the bifidobacterium lactis Bla80 ferment to form the direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome. The bifidobacterium lactis Bla80 plays a key role in regulating intestinal health and relieving constipation type irritable bowel syndrome, and is combined with streptococcus thermophilus ST81 and lactobacillus bulgaricus LB42, so that on one hand, three bacterial groups are mutually promoted, the fermentation process is facilitated, the growth of beneficial bacterial groups is promoted, on the other hand, the three bacterial groups are mutually matched, the effects of remarkable synergy are achieved on regulating intestinal bacterial groups and relieving constipation type irritable bowel syndrome, and the prepared fermented food can improve symptoms such as constipation and abdominal pain, enable defecation to be smoother, and effectively relieve constipation type irritable bowel syndrome. In addition, the invention adopts the specific combination of trehalose, malt paste, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80 as the protective agent, thereby having the effect of improving the stability of the prepared fermented food.
Detailed Description
In order to further describe the technical means adopted by the present invention and the effects thereof, the following description will further describe the technical solution of the present invention in connection with the preferred embodiments of the present invention, but the present invention is not limited to the embodiments.
The streptococcus thermophilus ST81 related to the following examples, comparative examples, application examples and comparative application examples is preserved in the China general microbiological culture Collection center, which is classified and named as streptococcus thermophilus Streptococcus thermophilus, and has a preservation number of CGMCC No.15752, a preservation date of 2018.05.11 and a preservation address of Beichen Xiyang area Beichen Xiylu No.1 and 3.
The following examples, comparative examples, application examples and comparative application examples were collected in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms), and were classified and named as De-type Lactobacillus bulgaricus Lactobacillus delbrueclii subsp.bulgaricus, which has a collection number of CGMCC No.15751, a collection date of 2018.05.11, and a collection address of North Chen West Lu No.1, 3 in the Chachiensis of Chachiensis.
The bifidobacterium lactis BLa80 of the following examples, comparative examples, application examples and comparative application examples is preserved in the general microbiological center of the China Committee for culture Collection of microorganisms, and is classified and named as bifidobacterium animalis subsp Bifidobacterium animalis subsp.Lactis, which is preserved with the number CGMCC No.15410, the preservation date is 2018.03.05, and the preservation address is North Chen West Lu No.1, 3 in the Yankee area of Beijing city.
Example 1
The embodiment provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, which comprises, by weight, 30 parts of streptococcus thermophilus ST81 fermentation product, 1.5 parts of lactobacillus bulgaricus LB42 fermentation product, 2.5 parts of bifidobacterium lactis Bla80 fermentation product, 12.5 parts of trehalose, 4 parts of maltodextrin, 1 part of beta-cyclodextrin, 3 parts of sucrose, 1.5 parts of glycerol, 0.05 part of mannitol and 0.2 part of tween-80. Wherein the viable count of the bifidobacterium lactis BLa80 in the direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome is 1 multiplied by 10 11 cfu/g。
The preparation method comprises the following steps:
(1) Inoculating bifidobacterium lactis BLa80 stored in an glycerol pipe into an MRS liquid culture medium according to the proportion of 2%, standing and culturing for 22 hours at 37 ℃, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2%, culturing at pH 5.5 and 37 ℃ for 11h, collecting bacterial liquid, centrifuging at 10000r/min for 10min, removing supernatant, and collecting bacterial mud to obtain bifidobacterium lactis BLa80 fermentation product.
The streptococcus thermophilus ST81 preserved by the glycerol pipe is inoculated into MRS liquid culture medium according to the proportion of 2 percent, and is subjected to stationary culture for 20 hours at 38 ℃ and activated for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 3%, culturing at pH 6.0 and 39 ℃ for 9h, collecting bacterial liquid, centrifuging at 8000r/min for 12min, discarding supernatant, and collecting bacterial mud to obtain Streptococcus thermophilus ST81 fermentation product.
Inoculating Lactobacillus bulgaricus LB42 stored in glycerol pipe into MRS liquid culture medium according to 2%, standing at 39deg.C for 18h, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2.5%, culturing for 10 hours at the pH of 5.8 and the temperature of 38 ℃, collecting bacterial liquid, centrifuging for 15 minutes at 6000r/min, removing supernatant fluid, and collecting bacterial mud to obtain the lactobacillus bulgaricus LB42 fermentation product.
(2) Uniformly mixing the bifidobacterium lactis BLa80 fermentation product, the streptococcus thermophilus ST81 fermentation product and the lactobacillus bulgaricus LB42 fermentation product obtained in the step (1) with trehalose, maltodextrin, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80, and performing vacuum freeze drying to obtain the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome.
Example 2
The embodiment provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, which comprises, by weight, 25 parts of streptococcus thermophilus ST81 fermentation product, 2 parts of lactobacillus bulgaricus LB42 fermentation product, 2.5 parts of bifidobacterium lactis BLa80 fermentation product, 14 parts of trehalose, 8 parts of maltodextrin, 1.5 parts of beta-cyclodextrin, 2 parts of sucrose, 2.2 parts of glycerin, 0.25 part of tween-80 and 0.05 part of mannitol.
The preparation method comprises the following steps:
(1) The streptococcus thermophilus ST81 preserved by the glycerol pipe is inoculated into MRS liquid culture medium according to the proportion of 2 percent, and is subjected to stationary culture at 37 ℃ for 22 hours, and is activated for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2%, culturing at pH 5.5 and 37 ℃ for 11h, collecting bacterial liquid, centrifuging at 10000r/min for 10min, discarding supernatant, and collecting bacterial mud to obtain Streptococcus thermophilus ST81 ferment.
Inoculating Lactobacillus bulgaricus LB42 stored in glycerol pipe into MRS liquid culture medium according to 2%, standing at 38deg.C for 20 hr, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 3%, culturing at pH 6.0 and 39 ℃ for 9h, collecting bacterial liquid, centrifuging at 8000r/min for 12min, discarding supernatant, and collecting bacterial mud to obtain lactobacillus bulgaricus LB42 fermentation product.
Inoculating bifidobacterium lactis BLa80 stored in an glycerol pipe into an MRS liquid culture medium according to the proportion of 2%, standing and culturing for 18 hours at 39 ℃, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2.5%, culturing at pH 5.8 and 38deg.C for 10h, collecting bacterial liquid, centrifuging at 6000r/min for 15min, discarding supernatant, and collecting bacterial mud to obtain Bifidobacterium lactis BLa80 fermented product.
(2) Uniformly mixing the streptococcus thermophilus ST81 fermentation product, the lactobacillus bulgaricus LB42 fermentation product and the bifidobacterium lactis Bla80 fermentation product obtained in the step (1) with trehalose, maltodextrin, beta-cyclodextrin, sucrose, tween-80, glycerol and mannitol, and performing vacuum freeze drying to obtain the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome.
Example 3
The embodiment provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, which comprises, by weight, 32 parts of streptococcus thermophilus ST81 fermentation product, 1.5 parts of lactobacillus bulgaricus LB42 fermentation product, 2.5 parts of bifidobacterium lactis Bla80 fermentation product, 13 parts of trehalose, 3 parts of maltodextrin, 1.5 parts of beta-cyclic alexin, 2 parts of sucrose, 0.01 part of mannitol, 1 part of glycerol and 0.2 part of tween-80.
The preparation method comprises the following steps:
(1) Inoculating Lactobacillus bulgaricus LB42 stored in glycerol pipe into MRS liquid culture medium according to 2%, standing at 37deg.C for 22 hr, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2%, culturing at pH 5.5 and 37 ℃ for 11h, collecting bacterial liquid, centrifuging at 10000r/min for 10min, discarding supernatant, and collecting bacterial mud to obtain lactobacillus bulgaricus LB42 fermentation product.
Inoculating bifidobacterium lactis BLa80 stored in an glycerol pipe into an MRS liquid culture medium according to the proportion of 2%, standing and culturing for 20 hours at 38 ℃, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 3%, culturing at pH 6.0 and 39 ℃ for 9h, collecting bacterial liquid, centrifuging at 8000r/min for 12min, discarding supernatant, and collecting bacterial mud to obtain bifidobacterium lactis BLa80 fermented product.
The streptococcus thermophilus ST81 preserved by the glycerol pipe is inoculated into MRS liquid culture medium according to the proportion of 2 percent, and is subjected to stationary culture for 18 hours at 39 ℃ and activated for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2.5%, culturing at pH 5.8 and 38deg.C for 10 hr, collecting bacterial liquid, centrifuging at 6000r/min for 15min, discarding supernatant, and collecting bacterial mud to obtain Streptococcus thermophilus ST81 ferment.
(2) Uniformly mixing the lactobacillus bulgaricus LB42 fermentation product, the bifidobacterium lactis BLa80 fermentation product and the streptococcus thermophilus ST81 fermentation product obtained in the step (1) with trehalose, sucrose, mannitol, maltodextrin, beta-cyclodextrin, glycerol and tween-80, and performing vacuum freeze drying to obtain the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome.
Example 4
The present example provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, which is different from example 1 only in that 12.5 parts of trehalose, 4 parts of maltodextrin, 1 part of beta-cyclodextrin, 3 parts of sucrose, 1.5 parts of glycerin, 0.05 part of mannitol and 0.2 part of tween-80 in example 1 are replaced by 13 parts of trehalose, 5.25 parts of maltodextrin, 2 parts of sucrose and 2 parts of glycerin, and the other components and the content are unchanged.
The preparation method is described in example 1.
Example 5
The present example provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, which is different from example 1 only in that 12.5 parts of trehalose, 4 parts of maltodextrin, 1 part of beta-cyclodextrin, 3 parts of sucrose, 1.5 parts of glycerin, 0.05 part of mannitol and 0.2 part of tween-80 are replaced by 15 parts of trehalose and 7.25 parts of maltodextrin in example 1, and other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 1
This comparative example provides a direct-vat set starter which differs from example 1 only in that 30 parts of the "Streptococcus thermophilus ST81 ferment, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Lactobacillus bifidus Bla80 ferment" of example 1 are replaced with 31.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Lactobacillus bifidus Bla80 ferment, and the other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 2
This comparative example provides a direct vat set starter which differs from example 1 only in that 30 parts of the "Streptococcus thermophilus ST81 ferment, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Bifidobacterium lactis Bla80 ferment" of example 1 are replaced by 31.5 parts of the Streptococcus thermophilus ST81 ferment, 2.5 parts of the Bifidobacterium lactis Bla80 ferment, and the other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 3
This comparative example provides a direct-vat set starter which differs from example 1 only in that 30 parts of the Streptococcus thermophilus ST81 ferment, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment and 2.5 parts of the Bifidobacterium lactis Bla80 ferment of example 1 are replaced by 34 parts of the Streptococcus thermophilus ST81 ferment and Lactobacillus bulgaricus LB42 ferment combination, wherein the mass ratio of the Streptococcus thermophilus ST81 ferment to the Lactobacillus bulgaricus LB42 ferment is 20:1, and the other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 4
This comparative example provides a direct vat set starter which differs from example 1 only in that 30 parts of the "Streptococcus thermophilus ST81 ferment of example 1, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Bifidobacterium lactis Bla80 ferment are replaced by 2.5 parts of the" Bifidobacterium lactis Bla80 ferment ", and the other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 5
This comparative example provides a direct vat set starter which differs from example 1 only in that 30 parts of the "Streptococcus thermophilus ST81 ferment of example 1, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Bifidobacterium lactis Bla80 ferment are replaced by 34 parts of the" Streptococcus thermophilus ST81 ferment ", and the other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 6
This comparative example provides a direct vat set starter which differs from example 1 only in that 30 parts of the Streptococcus thermophilus ST81 ferment, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Bifidobacterium lactis Bla80 ferment of example 1 are replaced by 34 parts of the Lactobacillus bulgaricus LB42 ferment, and the other components and contents are unchanged.
The preparation method is described in example 1.
Application example 1
The application example provides fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, which comprises, by mass, 0.003% of the direct-vat starter bacterial agent for relieving constipation-predominant irritable bowel syndrome of example 1, 17.5% of soybean meal, 5.5% of coconut milk, 2% of white granulated sugar, 1% of agar, 0.3% of pectin, 0.2% of citrus fiber, 0.03% of sea salt and the balance of water.
The preparation method comprises the following steps:
(1) Dissolving soybean powder in water, shearing at 80deg.C for 15min, standing for 10min, mixing, and heating to 90deg.C. Mixing agar, citrus fiber and white sugar at 70deg.C, shearing for 20min to dissolve, adding dissolved bean powder, coconut slurry, pectin and sea salt, and stirring.
(2) Homogenizing the mixture obtained in the step (1) at 60 ℃ and 20 MPa.
(3) Heating the homogenized mixture to 95 ℃ and preserving heat for 5min for sterilization.
(4) Cooling the sterilized mixture to 43 ℃, inoculating a direct-vat-set fermentation microbial inoculum for relieving constipation-type irritable bowel syndrome, fermenting at 44 ℃, stopping when the pH value of the system is below 4.5 and the acidity of the system is above 30 ℃, and demulsifying to obtain the fermented soybean milk for relieving constipation-type irritable bowel syndrome.
Application example 2
The application example provides fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, which comprises, by mass, 0.003% of the direct-vat fermentation microbial inoculum for relieving constipation-predominant irritable bowel syndrome of example 2, 25% of soybean meal, 3% of coconut slurry, 1% of white granulated sugar, 0.5% of agar, 0.1% of pectin, 0.5% of citrus fiber and the balance of water.
The preparation method comprises the following steps:
(1) Dissolving soybean powder in water, shearing at 70deg.C for 15min, standing for 10min, mixing, and heating to 80deg.C. Mixing agar, citrus fiber and white sugar at 60deg.C, shearing for 20min to dissolve, adding dissolved bean powder, pectin and coconut slurry, and stirring to obtain mixture.
(2) Homogenizing the mixture obtained in the step (1) at 65 ℃ and 20 MPa.
(3) Heating the homogenized mixture to 90 ℃ and preserving heat for 10min for sterilization.
(4) Cooling the sterilized mixture to 48 ℃, inoculating a direct-vat-set fermentation microbial inoculum for relieving constipation-type irritable bowel syndrome, fermenting at 47 ℃, stopping when the pH value of the system is below 4.5 and the acidity of the system is above 30 ℃, and demulsifying to obtain the fermented soybean milk for relieving constipation-type irritable bowel syndrome.
Application example 3
The application example provides fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, which comprises, by mass, 0.003% of the constipation-predominant irritable bowel syndrome relieving direct-vat starter of the embodiment 3, 15% of soybean meal, 9.5% of coconut milk, 5% of white granulated sugar, 0.2% of agar and 0.08% of sea salt, and the balance of water.
The preparation method comprises the following steps:
(1) Dissolving soybean powder in water, shearing at 75deg.C for 15min, standing for 15min, mixing, and heating to 85deg.C. Mixing agar and white sugar at 65deg.C, shearing for 15min to dissolve, adding dissolved bean powder, coconut slurry and sea salt, and stirring to obtain mixture.
(2) Homogenizing the mixture obtained in the step (1) at 70 ℃ and 18 MPa.
(3) Heating the homogenized mixture to 90 ℃ and preserving heat for 10min for sterilization.
(4) And cooling the sterilized mixture to 38 ℃, inoculating a direct-vat-set fermentation microbial inoculum for relieving constipation-type irritable bowel syndrome, fermenting at 39 ℃, stopping when the pH value of the system is below 4.5 and the acidity of the system is above 30 ℃, and demulsifying to obtain the fermented soybean milk for relieving constipation-type irritable bowel syndrome.
Application examples 4 to 5
Application examples 4 to 5 provide two kinds of fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, which are different from application example 1 only in that "0.003% of the direct-vat starter for relieving constipation-predominant irritable bowel syndrome of example 1" is replaced by 0.003% of the direct-vat starter for relieving constipation-predominant irritable bowel syndrome of examples 4 to 5, respectively, and the other components and contents are unchanged.
The preparation method is described in application example 1.
Comparative application examples 1 to 6
Comparative application examples 1 to 6 provided six fermented soybean milks differing from application example 1 only in that "0.003% of the direct fermentation starter for relieving constipation-predominant irritable bowel syndrome of example 1" was replaced with "0.003% of the direct fermentation starter of comparative examples 1 to 6", respectively, and the other components and contents were unchanged.
The preparation method is described in application example 1.
Test example 1
Stability test:
viscosity and acidity are important indexes for evaluating the taste of the fermented soybean milk, and are also important indexes for evaluating the quality stability of the fermented soybean milk. The viable count of bifidobacterium lactis Bla80 is an important influencing factor for the efficacy of fermented soybean milk and the regulation of intestinal health. Thus, the fermented soybean milk of application examples 1 to 5 was tested for changes in viscosity, acidity, pH, total number of lactic acid bacteria and viable count of bifidobacterium lactis BLa80 at shelf life (21 days of cold storage at 10 ℃) as follows:
Acidity was measured using an acidity meter (titration with 0.101mol/L NaOH standard solution using phenolphthalein as an indicator). The pH was measured with a pH meter (METTLER TOLEDO pH meter). Product viscosity was measured using a viscometer (NDJ-8S).
The total number of viable lactic acid bacteria (i.e., the total number of viable streptococcus thermophilus and lactobacillus bulgaricus) and the total number of viable bifidobacteria (i.e., the number of viable bifidobacterium lactis BLa 80) were detected according to the method of national standard GB 4789.35-2016. The results are shown in Table 1.
TABLE 1
/>
The results show that: the fermented soybean milk provided in application examples 1-5 has smaller viscosity change in shelf life and more stable texture state. The acidity and pH of the fermented soybean milk change to a smaller extent overall, indicating that the flavor and taste are more stable. During the cold storage period, the total number of lactobacillus in the fermented soybean milk is reduced, the viable count of the bifidobacterium lactis BLa80 is stable, and the viable count reaches 3.0X10 7 Above cfu/g, thus, the crowd suffering from constipation-predominant irritable bowel syndrome can achieve the effects of regulating intestinal health and relieving constipation by only drinking 300g of the fermented soybean milk provided in application examples 1-5 each day. The viscosity change, acidity change and pH change degree of the fermented soybean milk provided in application examples 4 and 5 are slightly larger than those of application example 1, and the viable count of lactic acid bacteria and bifidobacterium lactis Bla80 is slightly lower than that of application example 1, which shows that the specific combination of trehalose, malt paste, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80 is adopted as a protective agent to improve the stability of the prepared fermented soybean milk. In summary, application examples 1-5 are presented The viscosity, acidity and pH of the fermented soybean milk are less in change during refrigeration, the viable count of bifidobacterium lactis BLa80 in the fermented soybean milk is higher and stable, which indicates that the fermented soybean milk has better stability.
Test example 2
Safety evaluation:
the safety of the fermented soybean milk provided in application examples 1 to 5 was evaluated. 100 healthy volunteers (no allergy history to fermented soybean milk) were selected, and randomly divided into 5 groups of 20, each of the groups 1 to 5 taking 300ml of fermented soybean milk provided in application examples 1 to 5, respectively, per day. All volunteers did not take other drugs for treating gastrointestinal diseases and other fermented foods during the trial period. The test period was 1 month. And recording and comparing adverse reactions such as abdominal pain, abdominal distension, nausea and the like of each group of volunteers, and evaluating the safety of the fermented soybean milk.
The results show that: all volunteers do not have the phenomena of abdominal pain, abdominal distension, nausea and the like, which indicates that the fermented soybean milk provided in application examples 1-5 has no adverse reaction after being taken, and the safety meets the requirements.
Test example 3
Evaluation of effect of relieving constipation-predominant irritable bowel syndrome:
the fermented soybean milk provided in application examples 1 to 3 and comparative application examples 1 to 6 was evaluated for the alleviation of constipation-predominant irritable bowel syndrome. 100 volunteers with constipation type irritable bowel syndrome (including standard: according with related diagnosis standard of irritable bowel syndrome in Western medicine and Chinese medicine theory and confirmed diagnosis; volunteers have typical performances of constipation type irritable bowel syndrome; no allergic history to fermented soybean milk; understanding test content and participation in the test; excluding standard: having received other various medicines before starting the test, cardiovascular, renal and other organic lesions), were randomly divided into 10 groups of 10, each group of 1-9 was administered 300ml of fermented soybean milk provided in application examples 1-3 and comparative application examples 1-6, respectively, each group of 10 was a control group, and each person was administered 300ml of common commercial fermented soybean milk per day. The uniform drinking time of all volunteers was after breakfast and received uniform conventional diet regimen during the test period, including adjusting diet structure, increasing dietary salty taste and water intake, etc., without taking other drugs for treating gastrointestinal diseases and other fermented foods. The test period was 6 months.
Evaluation of curative effect: constipation symptoms and stool characteristics before and after taking fermented soybean milk by volunteers are observed, and the constipation symptom score is referred to a constipation symptom score table of the department of surgery of the Chinese medical society, which comprises 6 items of defecation difficulty, stool characteristics (BSS), defecation time, inexhaustible feeling, frequency and abdominal distension, wherein the score is set to 0-3, and the higher score indicates that the symptom is more serious. The volunteers of each group integrated for symptoms of abdominal distension, abdominal pain and bowel difficulty before and after the trialAre listed in Table 2. Data were processed using SPSS 20.0 statistical software, the metering data were t-checked, and the counting data were x 2 Checking, P<0.05 indicates that there is a statistical significance for the difference. The difference between symptom scores of the volunteers of each group before the test was not statistically significant (P>0.05)
TABLE 2
Comparing the clinical effects of each group: the curative effects are divided into cure, obvious effect, effective and ineffective. And (3) healing: the volunteers have normal defecation and normal stool texture, no abdominal distension and pain and no recurrence in 6 months; the effect is shown: the defecation condition and the stool texture of volunteers are obviously improved, the volunteers tend to be normal, most symptoms disappear, and recurrence is occasional within 6 months; the method is effective: the defecation condition and the stool texture of volunteers are improved, and the symptoms are reduced compared with those before treatment; invalidation: the volunteers had no improvement in defecation, stool texture, and abdominal distension and pain symptoms after treatment. The results are shown in Table 3.
TABLE 3 Table 3
The results show that: as can be seen from the data in tables 2 and 3, after the fermented soybean milk provided in application examples 1-3 is taken by constipation type irritable bowel syndrome patients, symptoms such as abdominal distension, abdominal pain and difficult defecation are obviously improved, which indicates that the fermented soybean milk provided in application examples 1-3 has an effect of remarkably relieving constipation type irritable bowel syndrome. The fermented soybean milk provided by comparative application examples 3, 5 and 6 does not contain bifidobacterium lactis Bla80, and only has a certain improvement effect on symptoms of abdominal distension after being taken, but can not relieve symptoms of abdominal pain, difficult defecation and the like of patients, and does not have the function of relieving constipation type irritable bowel syndrome, which means that bifidobacterium lactis Bla80 plays a key role in regulating intestinal health and relieving constipation type irritable bowel syndrome in the invention. The fermented soybean milk provided in application examples 1, 2 and 4 has a certain relieving effect on symptoms such as abdominal distension, abdominal pain and difficult defecation, but the effect is obviously inferior to that of application example 1, which shows that the three bacterial agents of streptococcus thermophilus ST81 ferment, lactobacillus bulgaricus LB42 ferment and bifidobacterium lactis BLa80 ferment are mutually matched and synergistically increased, and the fermented soybean milk has more remarkable effect on relieving constipation type irritable bowel syndrome than the independent combination of bifidobacterium lactis BLa80 ferment, streptococcus thermophilus ST81 ferment and bifidobacterium lactis BLa80 ferment and the combination of lactobacillus bulgaricus LB42 ferment and bifidobacterium lactis BLa80 ferment.
In summary, the invention creatively combines the streptococcus thermophilus ST81 ferment, the lactobacillus bulgaricus LB42 ferment and the bifidobacterium lactis Bla80 ferment to form the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome. The bifidobacterium lactis Bla80 plays a key role in regulating intestinal health and relieving constipation type irritable bowel syndrome, and is combined with streptococcus thermophilus ST81 and lactobacillus bulgaricus LB42, so that on one hand, three bacterial groups are mutually promoted, the fermentation process is facilitated, the growth of beneficial bacterial groups is promoted, on the other hand, the three bacterial groups are mutually matched, the bifidobacterium lactis Bla80 has a remarkable synergistic effect on regulating intestinal bacterial groups and relieving constipation type irritable bowel syndrome, and the prepared fermented food can improve symptoms such as constipation and abdominal pain, enable defecation to be smoother, and effectively relieve constipation type irritable bowel syndrome. In addition, the invention adopts the specific combination of trehalose, malt paste, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80 as the protective agent, and has the effect of improving the stability of the prepared fermented food.
The applicant states that the direct-vat set fermentation inoculant for relieving constipation-predominant irritable bowel syndrome and the preparation method and application thereof are described by the above examples and application examples, but the invention is not limited to the above examples and application examples, i.e. the invention is not necessarily limited to the above examples and application examples. It should be apparent to those skilled in the art that any modifications of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., fall within the scope and disclosure of the present invention.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.

Claims (23)

1. The direct-vat-set fermentation microbial inoculum for relieving constipation-type irritable bowel syndrome is characterized by comprising, by weight, 25-32 parts of streptococcus thermophilus ST81 with the preservation number of CGMCC No.15752, 1.5-2 parts of lactobacillus bulgaricus LB42 with the preservation number of CGMCC No.15751, 2.5 parts of bifidobacterium lactis BLa with the preservation number of CGMCC No.15410 and 18-36 parts of a protective agent;
the protective agent comprises, by weight, 12-18 parts of trehalose, 2.5-8.5 parts of maltodextrin, 1.0-1.5 parts of beta-cyclodextrin, 2-5 parts of sucrose, 1.2-2.4 parts of glycerol, 0.01-0.3 part of mannitol and 0.25 part of tween-800.02.
2. The direct-vat set starter for alleviating constipation-predominant irritable bowel syndrome according to claim 1, wherein the viable count of bifidobacterium lactis BLa80 in said direct-vat set starter for alleviating constipation-predominant irritable bowel syndrome is 1X 10 11 cfu/g or more.
3. A method for preparing the direct vat set starter for relieving constipation-predominant irritable bowel syndrome according to claim 1 or 2, comprising the steps of:
(1) Culturing and activating Streptococcus thermophilus ST81, and fermenting to obtain Streptococcus thermophilus ST81 fermented product; culturing and activating Lactobacillus bulgaricus LB42, and fermenting to obtain Lactobacillus bulgaricus LB42 fermented product; culturing and activating the bifidobacterium lactis BLa80, and fermenting to obtain a bifidobacterium lactis BLa80 fermentation product;
(2) Mixing the streptococcus thermophilus ST81 fermentation product, the lactobacillus bulgaricus LB42 fermentation product and the bifidobacterium lactis Bla80 fermentation product obtained in the step (1) with a protective agent to obtain the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome.
4. The process according to claim 3, wherein the temperature of the culture of Streptococcus thermophilus ST81, the temperature of the culture of Lactobacillus bulgaricus LB42 and the temperature of the culture of Bifidobacterium lactis BLa80 in step (1) are each independently 35 to 40 ℃.
5. The method according to claim 3, wherein the time for culturing Streptococcus thermophilus ST81, the time for culturing Lactobacillus bulgaricus LB42 and the time for culturing Bifidobacterium lactis Bla80 in step (1) are each independently 16 to 24 hours.
6. The process according to claim 3, wherein the fermentation temperature of Streptococcus thermophilus ST81 in step (1), the fermentation temperature of Lactobacillus bulgaricus LB42 and the fermentation temperature of Bifidobacterium lactis BLa80 are each independently 35 to 40 ℃.
7. The process according to claim 3, wherein the fermentation time of Streptococcus thermophilus ST81, the fermentation time of Lactobacillus bulgaricus LB42 and the fermentation time of Bifidobacterium lactis BLa80 in step (1) are each independently 9 to 12 hours.
8. The process according to claim 3, wherein the pH of the system during fermentation of Streptococcus thermophilus ST81 in step (1), the pH of the system during fermentation of Lactobacillus bulgaricus LB42 and the pH of the system during fermentation of Bifidobacterium lactis Bla80 are each independently 5.5 to 6.0.
9. The method of claim 3, wherein the fermentation product of step (1) after fermentation of streptococcus thermophilus ST81, after fermentation of lactobacillus bulgaricus LB42 and after fermentation of bifidobacterium lactis BLa80 further optionally comprises centrifugation.
10. The method of claim 9, wherein the rotational speeds of the centrifuges are each independently 6000 to 10000r/min and the times of the centrifuges are each independently 10 to 15min.
11. The method of claim 3, wherein said mixing in step (2) further comprises drying.
12. The method of claim 11, wherein the drying is freeze-drying.
13. Use of the direct vat set starter for alleviating constipation-predominant irritable bowel syndrome according to claim 1 or 2 in the preparation of a fermented food, wherein the inoculation amount of the direct vat set starter for alleviating constipation-predominant irritable bowel syndrome in the fermented food is 20-50g/T.
14. The use according to claim 13, wherein the fermented food product comprises any one of fermented soy milk, fermented soy flour, fermented milk or fermented milk powder.
15. Fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, wherein the raw materials for preparing the fermented soybean milk for relieving constipation-predominant irritable bowel syndrome comprise soybean flour, gum base, water and the direct-vat-set fermentation inoculant for relieving constipation-predominant irritable bowel syndrome according to claim 1 or 2.
16. The fermented soybean milk for relieving constipation-predominant irritable bowel syndrome according to claim 15, wherein the raw materials for preparing the fermented soybean milk for relieving constipation-predominant irritable bowel syndrome comprise, by mass, 0.002-0.005% of a direct-vat starter for relieving constipation-predominant irritable bowel syndrome, 10-28% of soybean flour, 3-20% of a gum base, and the balance water.
17. The fermented soybean milk for alleviating constipation-predominant irritable bowel syndrome of claim 15, wherein the gum base comprises any one or a combination of at least two of coconut milk, white sugar, agar, pectin, citrus fiber, or sea salt.
18. The fermented soybean milk for alleviating constipation-predominant irritable bowel syndrome of claim 17, wherein the gum base comprises coconut milk, white sugar, agar, pectin, citrus fiber, and sea salt.
19. The fermented soybean milk for alleviating constipation-predominant irritable bowel syndrome of claim 18, wherein the gum base comprises, in parts by weight, 3-10 parts of coconut milk, 1-5 parts of white sugar, 0.1-1 part of agar, 0.1-0.8 part of pectin, 0.2-0.8 part of citrus fiber and 0.01-0.1 part of sea salt.
20. A method for preparing fermented soybean milk for relieving constipation-predominant irritable bowel syndrome according to any one of claims 15-18, comprising mixing bean flour, gum base and water, homogenizing, sterilizing, inoculating a direct-vat-set fermentation starter for relieving constipation-predominant irritable bowel syndrome, fermenting, and demulsifying to obtain the fermented soybean milk for relieving constipation-predominant irritable bowel syndrome.
21. The method of claim 20, wherein the temperature of the mixing is 60-90 ℃.
22. The method of claim 20, wherein the temperature of the seeding is 38-50 ℃.
23. The method of claim 20, wherein the fermentation temperature is 38-50 ℃.
CN202111293299.0A 2021-11-03 2021-11-03 Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof Active CN114045233B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111293299.0A CN114045233B (en) 2021-11-03 2021-11-03 Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111293299.0A CN114045233B (en) 2021-11-03 2021-11-03 Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN114045233A CN114045233A (en) 2022-02-15
CN114045233B true CN114045233B (en) 2024-02-27

Family

ID=80206991

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111293299.0A Active CN114045233B (en) 2021-11-03 2021-11-03 Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114045233B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114146101B (en) * 2021-11-22 2023-07-07 微康益生菌(苏州)股份有限公司 Application of bifidobacterium animalis subspecies lactis BLa80 in preparation of medicines or foods for regulating intestinal motility
CN114480208B (en) * 2022-02-18 2023-09-29 微康益生菌(苏州)股份有限公司 Direct-vat-set probiotic starter for relieving immune disorder and application thereof
CN115558620B (en) * 2022-09-30 2023-10-20 微康益生菌(苏州)股份有限公司 Lactic acid bacteria freeze-drying protective agent and preparation method and application thereof
CN117736943A (en) * 2024-02-20 2024-03-22 山东中科嘉亿生物工程有限公司 Composite microbial agent for improving irritable bowel syndrome and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103893214A (en) * 2014-03-28 2014-07-02 北京和美科盛生物技术有限公司 Probiotics viable bacteria powder produced by whole oat solid-state mixed fermentation and preparation method of probiotics viable bacteria powder
CN111466440A (en) * 2020-06-03 2020-07-31 金华银河生物科技有限公司 Probiotic fermented milk capable of relieving constipation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103893214A (en) * 2014-03-28 2014-07-02 北京和美科盛生物技术有限公司 Probiotics viable bacteria powder produced by whole oat solid-state mixed fermentation and preparation method of probiotics viable bacteria powder
CN111466440A (en) * 2020-06-03 2020-07-31 金华银河生物科技有限公司 Probiotic fermented milk capable of relieving constipation

Also Published As

Publication number Publication date
CN114045233A (en) 2022-02-15

Similar Documents

Publication Publication Date Title
CN114045233B (en) Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof
EP3530277A1 (en) Chinese medicine healthcare preparations for slimming and weight loss
CN110946913B (en) Probiotic composition for relieving constipation and hemorrhoids
WO2013127146A1 (en) Lactobacillus plantarum able to relieve lead toxicity and use thereof
CN112999261B (en) Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof
CN112040792A (en) Composition for inducing defecation and losing weight and preparation method thereof
CN103110861A (en) Granular preparation for preventing infants from getting inflamed and adjusting intestines and stomach and preparation method thereof
CN117487683A (en) Probiotic composition with effects of resisting claustration, protecting stomach, promoting digestion and removing food retention and application thereof
CN106165780A (en) A kind of broiler Chinese medicine composite probiotics feed additive and preparation method thereof
CN110917174A (en) Oral probiotic capsule for regulating balance of female vaginal flora and preparation method thereof
CN111557404A (en) Digestion-aiding probiotic solid beverage and preparation method thereof
KR100716123B1 (en) Food composition comprising fermented dioscorea batatas decne. and the rhizoma thereof with lactic acid for preventing and improving constipation and obesity
CN113974043A (en) Prebiotics solid beverage and preparation method thereof
CN102742653B (en) Brain-strengthening and nerve soothing probiotic goat milk tablet and preparation method of brain-strengthening and nerve soothing probiotic goat milk tablet
CN106798755B (en) Probiotic composition with function of conditioning hyperplasia of mammary glands and application thereof
KR20170072003A (en) Method of manufacturing a fermented food that can help diabetes using the Hordeum vulgare L. and fermented food that has been produced by it
KR20110116344A (en) Composition for improving bowel function and relieving constipation containing dietary fiber, oligosaccharide and bacillus coagulans
CN114452308A (en) Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent
CN115462525B (en) Blood fat regulating composition and preparation method and application thereof
KR102165106B1 (en) A pill or granule comprising Dendropanax Morbifera extract for improving constipation disease and a method for producing the same.
CN112999305A (en) Solid preparation for regulating intestinal flora disturbance and preparation method thereof
CN114946954A (en) Solid beverage of probiotic compound composition containing traditional Chinese medicine components and preparation method
CN111165826A (en) Probiotic composition for improving renal function health
CN112237287B (en) Lactobacillus rhamnosus LR519 capable of relieving constipation and composition thereof
CN107233477A (en) A kind of composition, preparation method and application method for being used to treat porcine respiratory

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant